1038308-06-3

Upstream product

• 19241-24-8 4-(tert-butylbenzyl)isothiocyanate 
• 1492902-52-9 C₁₅H₂₃N₃OS 

Downstream Products

• 1492902-39-2 2-(4-(4-tert-butylphenyl)-5-isopropyl-4H-1,2,4-triazol-3-ylthio)-N-(2-chlorophenyl)acetamide 
• 1492902-40-5 2-(4-(4-tert-butylphenyl)-5-isopropyl-4H-1,2,4-triazol-3-ylthio)-N-(2-fluorophenyl)acetamide 
• 1492902-43-8 2-(4-(4-tert-butylphenyl)-5-isopropyl-4H-1,2,4-triazol-3-ylthio)-N-(4-methyl-2-nitrophenyl)acetamide 
• 1492902-41-6 N-(2-bromophenyl)-2-(4-(4-tert-butylphenyl)-5-isopropyl-4H-1,2,4-triazol-3-ylthio)acetamide 
• 1492902-42-7 N-(2-bromo-4-methylphenyl)-2-(4-(4-tert-butylphenyl)-5-isopropyl-4H-1,2,4-triazol-3-ylthio)acetamide 

Relevant academic research and scientific papers

Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

A series of novel 1,2,4-triazole thioacetanilide derivatives has been designed, synthesized and evaluated for their anti-HIV activities in MT-4 cells. Half of these compounds showed moderate to potent activities against wild-type HIV-1 with an EC50 ranging from 38.0 μM to 4.08 μM. Among them, 2-(4-(2-fluorobenzyl)-5-isopropyl-4H-1,2,4-triazol-3-ylthio)-N-(2-nitrophenyl) acetamide 7d was identified as the most promising compound (EC50 = 4.26 μM, SI = 49). However, no compound was active against HIV-2. The preliminary structure-activity relationships among the newly synthesized congeners are discussed.